PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
-3.33
Negative P/E while RVPH shows 200.48. Joel Greenblatt would examine path to profitability versus competitor.
No Data
No Data available this quarter, please select a different quarter.
7.08
P/B of 7.08 while RVPH has zero book value. Bruce Berkowitz would examine asset quality advantage.
-12.29
Negative FCF while RVPH shows P/FCF of 801.90. Joel Greenblatt would examine cash flow improvement potential.
-12.40
Negative operating cash flow while RVPH shows P/OCF of 801.90. Joel Greenblatt would examine operational improvement potential.
7.08
Fair value ratio of 7.08 while RVPH has zero value. Bruce Berkowitz would examine valuation methodology.
-7.50%
Negative earnings while RVPH shows yield of 0.12%. Joel Greenblatt would examine path to profitability.
-8.14%
Negative FCF while RVPH shows yield of 0.12%. Joel Greenblatt would examine cash flow improvement potential.
